Jagsonpal Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 06, 2025, recommended Final Dividend of 2.5 per equity share.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.4 pts less than Nifty Microcap 250 and 7.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported strong FY25 results with revenue from operations rising to Rs. 2,687.16 million from Rs. 2,087.02 million (about 29% growth). Net profit for the year jumped to Rs. 553.61 million from Rs. 224.63 million (around 146% growth), while EPS climbed to Rs. 8.26 from Rs. 3.40. The Board recommended a final dividend of Rs. 2.5 per share (125% on Rs. 2 face value), totalling about Rs. 166 million, subject to shareholder approval. The company completed a Rs. 940.12 million acquisition of Yash Pharma Laboratories' India and Bhutan business in dermatology and childcare, sold its Faridabad factory for Rs. 410 million (booking Rs. 233.59 million exceptional profit), and effected a stock split from Rs. 5 to Rs. 2 face value. Statutory auditor Walker Chandiok & Co LLP issued an unmodified (clean) opinion, and M/s. S S Kothari Mehta & Co. was appointed as Internal Auditor for FY26.
Strong earnings growth, healthy dividend yield, and clean audit opinion are positive signals for shareholders. The acquisition expands the company's dermatology and childcare portfolio, though investors should watch the pending customs duty appeal of Rs. 50.98 million as a potential overhang.